Clinical Trial

Burst Crossover Trial

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 24, 2024 (before its estimated August 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
Spinal cord stimulation (SCS) is a widely applied therapy to treat chronic neuropathic pain, and one of the most common indications is persisting radicular neuropathic pain following lumbar spine surgery. In traditional SCS therapies, the objective has been to replace the pain sensation with paresthesia. The anticipation is that the electrical current alters pain processing by masking the sensation of pain with a comfortable tingling or paresthesia. Although patients mostly cope with paresthesia, a significant proportion reports that the sensation is unpleasant. 'Burst' SCS utilizes complex programming to deliver high-frequency stimuli. This SCS technique seems to provide paresthesia-free stimulation, resulting in better pain relief of low back and leg pain then traditional tonic stimulation. The widespread use of SCS has not been backed by solid evidence. The absence of placebo-controlled trials has long been an important point of criticism, but due to the nature of the intervention with sensation of paresthesia, studies with placebo control have so far not been considered possible. When 'burst' SCS is used the stimulation is often unnoticed by the patient, allowing comparison with placebo stimulation. The aim of this randomized double-blind sham-controlled crossover trial is to evaluate the efficacy of 'burst' spinal cord stimulation for chronic radicular pain following spine surgery.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-05-09; most recent amendment 2024-12-18.
Trial Details
NCT Number NCT05372822
Lead Sponsor St. Olavs Hospital
Collaborators: Norwegian University of Science and Technology
Conditions Back Pain with Radiation, Pain, Postoperative
Enrollment 50 participants
Start Date 2021-05-01
Primary Completion 2025-08-15 (estimated)
Study Completion 2025-08-15 (estimated)
Updated on ClinicalTrials.gov 2024-12-24